Detalhe da pesquisa
1.
Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
Blood;
141(5): 481-489, 2023 02 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36095841
2.
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Ann Hematol;
100(4): 959-968, 2021 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33191481
3.
Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Ann Hematol;
100(8): 2141-2142, 2021 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34160650
4.
A Day 14 Endpoint for Acute GVHD Clinical Trials.
Transplant Cell Ther;
30(4): 421-432, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38320730
5.
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.
Blood Adv;
8(8): 2047-2057, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38324721
6.
GPR Expression in Intestinal Biopsies From SCT Patients Is Upregulated in GvHD and Is Suppressed by Broad-Spectrum Antibiotics.
Front Immunol;
12: 753287, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34777363
7.
Survival signal REG3α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease.
J Clin Invest;
128(11): 4970-4979, 2018 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30106382